Life Science Investing Broadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to Alcon
Life Science Investing Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
Life Science Investing Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
Life Science Investing Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
Life Science Investing STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
Life Science Investing Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory
Life Science Investing Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
Life Science Investing Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
Life Science Investing Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote "FOR" Alcon Merger
Life Science Investing Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation "AGAINST" STAAR Surgical Sale to Alcon
Life Science Investing Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
Life Science Investing Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer
Life Science Investing Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical
Goldgroup Enters Into Agreement To Sell Subsidiary Minera Apolo, S.A. de C.V., Disposing of Pinos Project
